Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices

D. Swan a,*, H. Enright b, R. Desmond b, G. Le b, E. El Hassadi c, B. Hennessy c, F. Lynott c, D. O’Keeffe d, M. Crowley e, L. Smyth f, K. Perera g, C. Jennings g, F. Ni Ainle h, J. Coll h, K. Ryan a, J. O’Donnell a, M. Lavin a, N. O’Connell a

a National Coagulation Centre, St James’ Hospital, Dublin, Ireland
b Tallaght University Hospital, Dublin, Ireland
c Waterford University Hospital, Waterford, Ireland
d University Hospital Limerick, Limerick, Ireland
e Cork University Hospital, Cork, Ireland
f St Vincent’s University Hospital, Dublin, Ireland
g Midland Regional Hospital Tullamore, Tullamore, Ireland
h Mater Misericordiae University Hospital, Dublin, Ireland

ARTICLE INFO

Keywords:
Thrombosis
Thrombocytopenia
VITT
COVID-19

ABSTRACT

Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic, several highly effective and safe vaccines have been produced at remarkable speed. Following global implementation of vaccination programmes, cases of thrombosis with thrombocytopenia following administration of adenoviral vector-based vaccines started being reported.

In this review we discuss the known pathogenesis and epidemiology of so-called vaccine induced thrombocytopenia and thrombosis (VITT). We consider the available guidelines, diagnostic laboratory tests and management options for these patients. Finally, we discuss important unanswered questions and areas for future research in this novel pathoclinical entity.

1. Introduction

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic has caused high levels of mortality and morbidity, leading to approximately 4.5 millions deaths world-wide [1]. Several vaccines have been developed with unprecedented speed, with four vaccines approved by early 2021. These vaccines are highly effective at reducing disease incidence and severity, with one vaccine dose reducing risk of hospitalization and death by over 80% [2].

In March 2021, three groups in Norway, Germany and the United Kingdom, reported the occurrence of thrombotic complications with thrombocytopenia in previously healthy patients who had recently received the AstraZeneca (AZ) ChAdOx1 nCoV-19 vaccine [3–5], with further reports in the following weeks and months [6,7]. A high proportion of cases had thrombosis at unusual sites, in particular, cerebral venous sinus thrombosis (CVST) and splanchnic vein thrombosis (SVC).

Cases associated with the Johnson & Johnson (J&J) vaccine (AD26.COV2.S) have since been published [8]. This syndrome, termed vaccine induced thrombocytopenia and thrombosis (VITT), vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombosis with thrombocytopenia syndrome (TTS), is a rare complication of vaccination, limited to the replication-defective adenoviral vector-based SARS CoV-2 vaccines. The AZ vaccine uses a chimpanzee adenoviral vector encoding a modified membrane-bound SARS CoV-2 spike protein that does not shed, and the J&J vaccine uses a recombinant human adenoviral vector that encodes an unmodified spike glycoprotein. Cases of VITT are almost exclusively seen following adenoviral vector-based vaccines with only rare reports in association with mRNA-based vaccines [9].

This review summarises the current understanding of the pathogenesis and epidemiology of VITT and compares the initial published cases to more recent reports including experience from a cohort of Irish patients. The available guidelines, diagnostic laboratory tests and management options for VITT are discussed and future areas of research are...
highlighted.

2. Pathogenesis

The similarities in clinical presentation between initial patients with VITT and with heparin-induced thrombocytopenia (HIT) led to the recognition that the pathogenesis of both conditions might be similar. The groups who first reported this phenomenon independently identified that affected patients had high circulating levels of immunoglobulin G (IgG) antibodies against platelet factor 4 (PF4), detected by enzyme-linked immunosorbent assay (ELISA) [3-5]. HIT is characterized by thrombosis and thrombocytopenia secondary to antibodies directed against PF4-heparin complexes, which crosslink FcγRIIa receptors (FcγRIIa) on platelets, causing platelet activation, degranulation and aggregation. FcγRIIa is also present on monocytes, endothelial cells and neutrophils. Anti-PF4 binding leads to enhanced tissue factor expression, thrombin generation and formation of neutrophil extracellular traps (NETs), generating a hypercoagulable state [10]. Atypical HIT is a rare form of HIT, occurring in the absence of prior heparin exposure, in which the anti-PF4 antibodies are heparin-independent [11]. Similarly, anti-PF4 antibodies in patients with VITT are able to bind to platelets and other cells via FcγRIIa receptors, leading to platelet activation, consumption and thrombosis, in the absence of heparin [3].

The pathogenesis of HIT relies upon the differential electric charges between PF4 and heparin. PF4 is a positively charged cation stored in platelet alpha-granules. PF4 binds to heparin, which is strongly anionic (termed a polyanion), producing a conformational change and exposing a new epitope, thus stimulating autoantibody formation [12]. In patients with VITT, it is hypothesized that anionic surfaces present in adenoviral vector-based vaccines are performing a similar role to heparin in HIT.

One group has shown that VITT anti-PF4 antibodies consistently bind within the heparin-binding site of PF4, whereas HIT anti-PF4 antibodies may bind to other sites within PF4. This may partly explain the mechanism by which VITT antibodies mimic the effect of heparin, by binding a similar site on PF4, enabling PF4 tetramers to cluster and form immune complexes, leading to FcγRIIa-dependent platelet activation [13].

Greinacher et al. have recently published important results suggesting a two-step mechanism for thrombosis in VITT [14]. In the first step, vaccine components including adenovirus hexon protein, bind to PF4, induce a conformational change and expose a neoantigen. Proinflammatory responses to vaccination amplify antibody production. The AZ vaccine contains EDTA (Ethylenediaminetetraacetic acid), which increases vascular permeability, a hallmark of inflammation [15]. In addition, around 50% of proteins within the AZ vaccine are derived from the T-Rex HEK293 human embryonic kidney-derived production cell line. The immunogenicity of these proteins and impact on inflammation has yet to be established [16]. In the second step, five to 20 days after vaccination, anti-PF4 VITT antibodies have been produced in sufficient quantities to activate platelets and other cellular lineages via FcγRIIa receptors. Thrombi are composed of fibrin, erythrocytes and platelet aggregates. Historically, arterial thrombi were considered to be ‘white’ clots, comprised mainly of platelets and thus treated with antplatelet agents, whereas venous thrombi were ‘red’ clots, made predominantly of fibrin and red cells requiring anticoagulation [17]. VITT is characterized by thrombocytopenia alongside decreased fibrinogen and increased D-Dimers, suggesting involvement of both platelets and the coagulation system. Postmortem analysis of two patients who died as a consequence of extensive thrombosis and intracranial haemorrhage revealed increased complement components on vascular endothelial surfaces, the presence of platelet aggregates lining small and medium sized vessel walls and inflammatory cells, particularly monocytes. These findings indicate further involvement by both the innate immune system and complement activation in the aetiology of thrombosis in VITT [18].

Greinacher et al. showed that incubation of human neutrophils with VITT patient serum induced NETosis in a platelet dependent fashion. Immunohistochemical analysis of samples from CVST in two VITT patients showed abundant activated neutrophils and evidence of enhanced NETosis compared with similar material from a patient with CVST not caused by VITT [14]. The precise interplay between platelet activation, inflammation, the complement system and the coagulation cascade in the pathogenesis of VITT has yet to be elucidated and may be key to optimizing management of these cases in future.

3. Epidemiology

As of April 4, 2021, 169 cases of CVST and 53 of SVT had been reported to the European Drug Safety Database, EudraVigilance. Updated guidance concerning the AZ vaccine released in June 2021 proposes a risk of thrombosis with thrombocytopenia of up to 1/10,000 [19]. The initial estimated incidence of VITT based on the primary case reports was approximately 1/100,000 exposures [20]. As of September 22, 2021, the UK MHRA (Medicines and Healthcare products regulatory agency) has received 419 reports of cases of thrombosis and thrombocytopenia following approximately 48.8 million doses of the AZ Covid-19 vaccine, which remains relatively consistent with this initial estimate [21]. 89% of reported cases in the UK occurred after the first vaccine dose. Rates associated with the J&J vaccine are possibly slightly lower, with 47 cases out of 14.8 million doses administered in the United States reported to the CDC (Centres for disease control and prevention) by September 22, 2021 [22]. The MHRA has also received reports of 18 cases of thrombosis and thrombocytopenia following the Pfizer mRNA vaccine and two after the Moderna vaccine. Whether these represent true cases of VITT is not certain from the information available [21].

4. Published case series and cases within Ireland: changing demographics and outcomes

A summary of reported case series is presented in Table 1 [3,6,8,23]. Considering five initial case reports, concerning patients identified in March and April 2021, 52 patients are described, 51 of whom received the AZ vaccine and 1 the J&J vaccine [3,6,8]. There was a strong female predominance in these first initial reports, ranging from 61% to 100% of cases. The average time between vaccination and symptom onset was between approximately 8-12 days and up to 24 days. CVST was the most frequently observed thrombotic complication followed by SVT. A mean platelet nadir of 30-40 x 10^9/L was seen across the reports, D-dimers were consistently extremely elevated, at levels higher than usually seen in acute VTE, and hypofibrinogenaemia was found in around half of patients. Mortality ranged from 25 to 60%, predominantly as a consequence of intracranial haemorrhage in patients with CVST. PF4 ELISA results were positive in nearly all cases, usually with higher optical density (OD) readings than seen in patients with HIT. Several functional assays were used in a subset of patients. Modified heparin induced platelet aggregation (HIPA) and PF4-induced platelet aggregation (PIPA) assays were positive in the majority of cases, whereas 1 in 10 patients reported by See et al. tested positive using the serotonin release assay (SRA) [6].

From March to August 2021, the National Coagulation Centre in Ireland has identified 10 probable cases of VITT [24]. Nine patients received AZ and one received J&J. 50% were female and the mean age was 42 years (range 21–63). Four patients were over the age of 50 years. Mean time from vaccination to hospital presentation was 17.7 days (median 14 days). Two patients had no confirmed thrombotic event and eight patients had venous thrombosis of which some had multiple events: PE [5], CVST [3], DVT [3] or SVT [2]. One patient presented initially with a central venous catheter-associated thrombosis and a normal platelet count and was treated with therapeutic low molecular weight heparin. Later, this patient developed thrombocytopenia and recurrent acute lower limb arterial thrombosis requiring emergency embolectomy and fasciotomies. As the patient had recently received an adenoviral vector vaccination, both HIT and VITT were considered...
### Table 1
Demographics and outcomes of published cases of VITT.

| Paper          | Cases (n) | Age (years) | Female (%) | Vaccine | Days to symptom onset (range) | Thrombosis | Platelet nadir x $10^9/\text{l}$ (range) | Fibrinogen | D-dimer | PF4 ELISA | Functional assay | Treatment | Mortality (%) |
|----------------|-----------|-------------|------------|---------|-------------------------------|------------|--------------------------------|------------|---------|-----------|------------------|-----------|---------------|
| Schultz et al. | 5         | Mean 41 (32–54) | 80         | AZ      | 8 (7–10)                      | 5 CVST 1 SVT 9 CVST 3 SVT 3 PE 4 other | 27 (30–70) | Reduced in 60% | High elevated in 100% | OD range 2.9–3.8 | Positive in 4 of 5 | IVIg and steroids in 4 patients | Not reported | 60 |
| Greinacher et al. | 11        | Mean 30 (22–49) | 82         | AZ      | 8 (5–16)                      | 13 CVST 4 PE 2 portal vein 2 ischaemic strokes | 44 (7–113) | Reduced in 57% | High elevated in all tested (n=7). Mean 35 mg/l (1.8–142) | OD >2 in 8 of 9 | Positive in 4 of 5 | Positive in all tested (n=9) | Not reported | 55 |
| Scully et al.  | 23        | Mean 46 (21–77) | 61         | AZ      | 12 (6–24)                     | 12 CVST 8 non-CVST | 46 (9–127) | Reduced in 58% | Elevated in 100%. Mean 1.1–112 mg/l | OD >2 in 8 of 9 | Positive in 1 of 10 | Non-heparin anticoagulation in 10 (6 initially received heparin), IVIg in 7, IVIg and steroids in 3, platelet transfusions in 4 patients | Not reported | 30 |
| Muir et al.    | 1         | 48           | 100        | J&J     | 14                            | 13 CVST 1 CVST 1 SVT | 13 | Reduced | 117.5 mg/l | OD 2.55 | ND | Argatroban and IVIg | Critically ill at time of writing | 25 |
| See et al.     | 12        | 18–<60       | 100        | AZ      | 9 (6–15)                      | 12 CVST 8 non-CVST | 46 (9–127) | Reduced in 58% | Elevated in 100%. Mean 1.1–112 mg/l | OD >2 in 8 of 9 | Positive in 1 of 10 | Non-heparin anticoagulation in 10 (6 initially received heparin), IVIg in 7, IVIg and steroids in 3, platelet transfusions in 4 patients | Not reported | 22 |
| Pavord et al.  | 220 (170 definite, 50 probable) | Median 48 (18–79) | 55         | AZ      | Median 14 (5–48)               | 110 CVST (50%) 43 DVT 63 PE 21 DVT/PE 41 SVT 47 arterial events | 47 (6–344) | Median 2.2 g/l (range 0.3–4.4) | Median 24,000 mcg/l (range 5000–80,000) | Positive in 198 of 220 patients tested | Not reported | Non-heparin anticoagulation 68%, IVIg 1 dose 72%, 2 doses 11%, corticosteroids 26% | 22 |

CVST (cerebral venous sinus thrombosis), DVT (deep vein thrombosis), IVIg (intravenous immunoglobulin), OD (optical density), PE (pulmonary embolism), SRA (serotonin release assay), SVT (splanchnic vein thrombosis).

a AZ (AztraZeneca); J&J (Johnson and Johnson).
possible, but it was noted that HIPA was negative and PIPA was positive. After diagnosis with VITT, all patients were therapeutically anticogulated with a direct oral anticoagulant (DOAC), two receiving the direct thrombin inhibitor argatroban, and six received intravenous immunoglobulin infusions. There have been no deaths.

The mean platelet count on presentation was 106 x 10^9/l (range 24-258 x 10^9/l), with a nadir of 89 x 10^9/l (range 24-230 x 10^9/l). Mean fibrinogen was 2.6 g/l (median 2.3 g/l), with hypofibrinogenaemia identified in three cases. D-dimers were highly elevated in nine of 10 cases, with an average of >10 mg/l (normal <0.5 mg/l). Particle gel immunoassay screening was poorly sensitive, with only 1 positive result in 5 cases tested, in keeping with other case-series and published data [25]. PF4 IgG ELISA (Immucor) was strongly positive in all 10 cases. The mean OD was 2.3 (upper limit of normal 0.352 OD), with nine of 10 cases having an OD >2, and all samples showing strong inhibition by heparin (mean 99%). The HIPA was positive in three out of 10 cases, whereas the PIPA was positive in 9 of 10 cases (1 negative sample was possible, but it was noted that HIPA was negative and PIPA was positive). After diagnosis with VITT, all patients were therapeutically anticogulated with a direct oral anticoagulant (DOAC), two receiving the direct thrombin inhibitor argatroban, and six received intravenous immunoglobulin infusions. There have been no deaths.

In comparison with the first case series published, our cohort have a higher platelet count, an equal sex distribution, fewer CVSTs and no mortality. A recent, larger publication of 220 definite or probable VITT cases from the UK reported a slight female excess of 55%, median age of 48 years and a median platelet count of 47 x 10^9/l. CVST occurred in 50% and D-dimers were markedly elevated. Mortality was 22% overall and 73% in patients with a baseline platelet count of <30 x 10^9/l with concomitant intracranial haemorrhage (ICH) [23]. Data from the MHRA have also reported no clear sex predominance, with 51% of 417 cases being female, and a rate of CVST of 36%, similar to our findings. Average age was 46 years for those with CVST and 54 years for other cases, however patients were affected up to the age of 93 years [21]. Mortality in the 417 cases was 17%, far lower than rates initially reported.

It has been suggested that the over-representation of female cases in initial reports may reflect differences in national rollout schedules. Norway and Germany concentrated on early vaccination of healthcare workers, who are disproportionately female [26]. Discrepant mortality rates may reflect variable rates of CVST within studies, and the now heightened awareness and prompt treatment of this condition. Pavord et al. showed that mortality was associated with CVST and worsening coagulopathy. Hazard ratios (HR) for mortality were increased in the presence of certain clinical features including CVST (HR 2.7, 95% confidence interval [CI] 1.4–5.2), every 50% decrease in platelet count (HR 1.7, 95% CI 1.3–2.3), every 10,000 mcg/l increase in D-Dimer (HR 1.2, 95% CI 1.0–1.3) and every 50% decrease in baseline fibrinogen level (HR 1.7, 95% CI, 1.1–2.5) [23]. Initial cases were very advanced before VITT was recognized, leading to a higher proportion of patients with severe disease manifestations such as marked thrombocytopenia, coagulopathy and ICH, which may account for the higher mortality rates seen initially in comparison to recent publications and the experience in Ireland.

5. Approach to the patient with suspected VITT

5.1. Published guidelines

Following the identification of VITT, several bodies have rapidly formulated and released guidelines regarding diagnosis and management. Perhaps unsurprisingly, given the limited available information on which to form these recommendations, significant differences exist between documents, and a number of recommendations have been amended since initial release [27–33]. A summary of the available guidelines is presented in Table 2. The interval to presentation post-vaccination for consideration of VITT varies significantly from up to 16 days–42 days. The International Society on Thrombosis and Haemostasis (ISTH), Thrombosis Canada guidelines and those from the National Institute for Health and Care Excellence (NICE) do not require either a positive ELISA or functional assay, the German guidelines stipulate both, and the American Society of Hematology (ASH) and the UK Expert Haematology Panel (EHP) require a positive PF4 ELISA only. The German guidelines are the only ones which do not mandate thrombocytopenia at diagnosis. The ISTH and ASH recommendations specify a D-Dimer of >4 times the upper limit of normal and the UK EHP merely states that D-Dimers should be elevated.

Given the lack of consensus regarding diagnostic criteria in this newly discovered condition and the fact that early detection and management of less advanced disease may profoundly impact outcomes, clinician awareness and input from senior clinical decision makers are of
paramount importance in the investigation and management of VITT.

5.2. Laboratory testing

Patients who warrant further investigation should have samples sent for confirmatory lab testing. There are several tests used to confirm the presence of clinically relevant HIT antibodies. These differ in various technical aspects including the source of PF4 and polyanion used, which alter their ability to reliably detect VITT antibodies. Serum samples from 12 patients with confirmed VITT by functional testing were used to assess the utility of three ELISA tests (Immucor, Hyphen and Stago), a particle gel immunosay (PaGIA), a chelatimlogenium immunoassay (CLIA) and lateral flow immunosay (LFA). The PF4 ELISAs performed well, with calculated sensitivities of 100%, 92% and 91% for the respective assays. PaGIA, CLIA and LFA had sensitivities of <1% and should not be used to screen suspected VITT [25]. A functional test is subsequently required to confirm that the VITT antibodies detected lead to platelet aggregation in vitro. Available tests include a modified HIPA test with the addition of PF4 (PIPA) [3], heparin-induced multiple electrode aggreometry (HIMEA) [4] and SRA, which had poor specificity in the report by See et al. but has been used successfully elsewhere [6]. There are also flow cytometry-based tests, such as the PF4-induced flow cytometry-based platelet activation assay (PIFPA) [34] and the ‘procoagulant platelets’ test, which uses annexin V as a flow cytometric marker of donor platelet activation following exposure to patient serum [35]. These tests vary in their requirement for washed platelet or whole blood, serum or plasma, and volume of sample (summarized in Table 3). They are highly specialized and should only be performed by experienced centres, with choice of test dependent on available expertise.

5.3. Management of suspected or confirmed VITT

Patients with suspected or confirmed VITT should be treated without delay. We next discuss the therapies recommended or suggested by the published guidelines, and the relevant supporting evidence. The mainstay of treatment comprises intravenous immunoglobulins and non-heparin anticoagulation.

5.4. Intravenous immunoglobulins (IVIg)

Greinacher et al. demonstrated that PF4-dependent platelet activation in VITT is mediated by binding to FcγRIIA. Platelet activation was inhibited by both the anti-FcγRIIA monoclonal antibody IV.3, and by the addition of IVIg (Privigen) [3]. Three VITT patients with predominantly arterial thrombosis received IVIg with consistent platelet increments in platelet count seen in two, and an initial response in the third. IVIg treatment did not significantly impact ELISA OD results, indicating lack of inhibition of VITT antibody binding to PF4. IVIg did however lead to reduced reactivity by SRA in the presence of PF4, demonstrating a reduction in the functional ability of VITT antibodies to induce platelet aggregation following IVIg treatment [36]. Based on current evidence, IVIg is the treatment most likely to modify disease course. The majority of guidelines recommend 2 doses of 1 g/kg (NICE suggests 1 dose with clinical review). The EHP advise IVIg irrespective of degree of thrombocytopenia [30], Thrombosis Canada have advised its use in severe or life-threatening thrombosis [28], and the ISTH recommend in cases with a platelet count of <50 x 10^9/l [27].

5.5. Anticoagulation

The available guidelines are consistent in recommending the use of non-heparin anticoagulants in patients with thrombosis. Whether heparin adversely affects outcomes in VITT is not definitively known. An early publication described worsened thrombosis in one patient receiving heparin [5]. A review of 70 patients with VITT and CVST reported reduced death or dependency in patients who received non-heparin anticoagulants (36% of 50 patients) compared with those who did not (75% of 20 patients) [37]. Conversely, the recent larger UK dataset reported a mortality rate of 20% in patients treated with heparin, versus 16% in those who received alternate anticoagulants. The authors of this review concluded that heparin did not appear harmful [23]. However, the sample size in these publications is small, and until it is conclusively known whether heparin is safe in patients with VITT, its use is not recommended. Suitable alternatives, which have proven safe and effective in HIT include parenteral direct thrombin inhibitors argatroban and bivalirudin, direct oral anticoagulants without a heparin lead-in phase (apixaban and rivaroxaban), fondaparinux or danaparoid [38]. Therapeutic dose anticoagulation is safe in patients with a platelet count of 50 x 10^9/l or higher [39].

Whether therapeutic anticoagulation is required in patients with VITT without documented thrombosis, similar to patients with HIT, is not certain. The NICE guidelines and EHP suggest consideration of non-heparin VTE prophylaxis in patients with VITT without confirmed thrombosis, but with thrombocytopenia and D-Dimers >4000 mcg/l [30,33]. The other guidelines do not discuss VTE prophylaxis in suspected VITT patients.

5.6. Blood product support

Historically, HIT was thought to be a prothrombotic condition in which bleeding was a rare manifestation. Although this belief has been challenged in recent years [40], the rate of haemorrhagic complications in VITT patients seems to be higher than seen previously in the setting of HIT. This is particularly true of those with CVST, in which ICH may be seen in up to 80% of cases, with high associated morbidity and mortality [3–6]. Blood product support to manage coagulopathy may therefore be more important in this novel disease entity.

Fibrinogen levels should be maintained at 1.5 g/l or higher using fibrinogen concentrate or cryoprecipitate depending on national and
local policy. Platelet transfusions have been associated with increased thrombosis and mortality rates in HIT, although this remains an area of debate [41,42]. At the time of writing, it is unclear whether platelet transfusions will exacerbate the pathogenesis of VITT. As such, they are not recommended routinely, but may be considered in thrombocytopenic patients requiring neurosurgery and in the context of active bleeding [31]. Reduced ‘critical care’ dosing of argatroban is an option in patients with a platelet count $<50 \times 10^9/\text{l}$ as an alternative to transfusing platelets in order to facilitate full therapeutic dose anti-coagulation [30].

5.7. Other treatments

5.7.1. Corticosteroids

Whether corticosteroids are beneficial in VITT is unknown. There are case reports showing benefit in patients with HIT [43,44], and the combination of IVIg with methylprednisolone raises platelet counts faster in childhood ITP, another autoantibody-mediated condition, than IVIg alone [45]. NICE recommends corticosteroids if IVIg treatment is insufficient, the ISTH advocates their use in patients with a platelet count $<50 \times 10^9/\text{l}$, and the EHP guidelines suggest upfront corticosteroids in patients with CVST due to high mortality rates amongst this cohort [27,30,33].

5.7.2. Plasma exchange

Plasma exchange may be of benefit. A 90% survival rate was reported following use of plasma exchange in 17 patients with CVST and/or extensive thrombosis, using solvent detergent plasma (Octaplas). The two deaths were both in patients with intracranial haemorrhage at presentation [23]. Successful use of plasma exchange was also reported in three cases of persistent thrombocytopenia and progressive thrombosis despite IVIg [46]. The UK EHP recommends early plasma exchange in those with extensive thrombosis and a platelet count $<30 \times 10^9/\text{l}$ [30]. The ISTH recommendations are for patients with refractory thrombocytopenia (platelets $<30 \times 10^9/\text{l}$) after IVIg and steroids [27].

5.7.3. Rituximab

There is no evidence that the anti-CD20 monoclonal antibody Rituximab improves outcomes in VITT, with anecdotal use in HIT only [47]. The UK guidelines both suggest consideration of rituximab in patients refractory to IVIg and plasma exchange, although there is no evidence to support this approach at the current time [30,33].

5.7.4. Eculizumab

Activation of complement in VITT has been demonstrated in post-mortem findings [18]. Eculizumab, a monoclonal antibody directed against complement C5, prevents terminal complement activation. A case report describes its use in two cases of VITT, one with thrombotic microangiopathy and renal failure, and the other with a severe thromboembolic event following IVIg administration [48]. The ASH guidelines include eculizumab as a treatment option, however supportive evidence is lacking [31].

6. Future directions

The astute observation of acute thrombosis and thrombocytopenia after vaccination with adenoviral-vector-based SARS CoV-2 vaccine viruses, and the subsequent description and characterization of VITT happened with great rapidity. At the time of writing, much remains unknown, including the pathogenesis of the antibody response against PF4, the varying prevalence of VITT following vaccination with the AZ versus J&J vaccine, the reason for disproportionate numbers of CVST and SVT in cases of VITT, and the risk associated with revaccination. The majority of cases have occurred following the first vaccine dose (89% in the MHRA report [21]). Data is awaited on outcomes for these patients after a second vaccine dose with an mRNA-based vaccine.

VITT is a rare complication following receipt of an adenoviral-vector derived SARS CoV-2 vaccine. No risk factors, other than a younger age, have been consistently associated with development of VITT, and there currently are no means of predicting which individuals might be at greater risk. A population-based study reported a prevalence of anti-PF4 antibodies of 1.2% in nearly 500 AZ-treated patients [49]. Low-titre anti-PF4 antibodies have been demonstrated in similar proportions of individuals receiving the adenoviral vector-based AZ and the mRNA-based Pfizer vaccines (8% and 6.8% respectively), with antibodies also present in a number of patients prior to vaccination. OD readings were generally less than 1 and none of these antibodies activated platelets in the presence of PF4 [50,51]. These antibodies are likely induced by the mild systemic inflammation which accompanies all vaccinations against Covid-19 and do not herald development of VITT. This is perhaps not surprising, given that similar antibodies are detected in 25–50% of patients post-cardiac surgery, whereas the rate of HIT is far lower [20,52].

Although VITT is thought to be primarily mediated by platelet activation, anti-platelet agents are not recommended by the available guidelines due to concerns regarding increased bleeding risk and unclear evidence of potential benefit [27–31,33]. One group assessed the ability of serum from four confirmed VITT cases to induce platelet aggregation in the presence of the COX inhibitor indomethacin and the P2Y12 inhibitor ticagrelor. Both these agents, as well as heat inactivation of sera, impaired aggregation, which the authors hypothesized might reflect a contribution from complement [53]. Aspirin has been shown to only partly inhibit platelet aggregation induced by anti-PF4 antibodies in serum from patients with HIT [54], and is not recommended as part of the treatment of either HIT or VITT [55]. One hypothesis considers the structure of clots, whereby a core of highly activated platelets is surrounded by a looser shell of less activated platelets. Thrombin activity and fibrin formation are found mainly in the densely packed core, where close proximity means fibrinogen is better able to bind to platelet glycoprotein (GP) IIb/IIIa [56]. It has been postulated that perhaps platelet activation is so robust in VITT that dense clots are formed within circulatory beds, consuming platelets and fibrinogen via GPIIb/IIIa, producing the picture of thrombosis and coagulopathy observed [57]. Addition of the GPIIIa/IIb inhibitor epitifibatide to donor platelets treated with VITT serum inhibits aggregation [53], however use of such potent antiplatelet agents in clinical practice would likely be associated with an unacceptable bleeding risk. At the current time, the value of antiplatelet therapy in management of VITT is unproven.

The effects of inhibitors of FcγRIIa and its downstream signaling pathways on platelet aggregation in VITT were also analysed. Platelet activation was abolished by the monoclonal antibody IV.3 as seen previously [3], but also by the Src (sarcoma genes tyrosine kinases) inhibitor dasatinib, the Syk (spleen tyrosine kinase) inhibitor entosplentinib and the Btk (bruton tyrosine kinase) inhibitors ibrutinib and riluzabrutinib [53]. Further consideration of the cellular pathways involved in this condition may shed light on how to optimize future treatment strategies.

Another important question concerns duration of anticoagulation. VTE in patients with HIT is considered to be provoked by a transient reversible risk factor, warranting 3 months of therapeutic anticoagulation [55]. Consensus regarding duration of anticoagulation in patients with HIT without thrombosis has not been reached, with recommendations ranging from until resolution of thrombocytopenia to 4–6 months [58]. It seems reasonable to treat patients with VITT and proven thrombosis for a minimum of 3 months. However whether it is safe to discontinue anticoagulation after this period in cases with persistent evidence of anti-PF4 antibodies by functional assays is unknown. Greinacher et al. recently reported results from a study of 35 confirmed cases of VITT. After a median follow-up of 11 weeks, 66% had a negative PIPA. In 14 of the 15 patients with follow-up of over three months duration, the PIPA became negative within a median of 12 weeks. Five of these cases received a second vaccine dose with an
mRNA-based vaccine. Based on these results, the authors have suggested that second vaccination may be considered once functional antibody assays are negative, or after 12 weeks where these are not available [59]. In the Irish patient cohort, one case had evidence of a reduction in OD over time in serial PF4 ELISAs (OD 1.84 at 5 weeks and 0.86 at 14 weeks with a negative PIPA). Conversely, another two cases still have strongly positive OD >2 after 13 weeks, with no reduction in intensity over time, and a positive PIPA. The time at which anticoagulation can be safely discontinued, especially in patients with confirmed thrombosis and ongoing laboratory evidence of detectable, functional antibodies remains uncertain, and an important area of ongoing investigation.

Goverance

This clinical audit has been approved by the local institutional research and innovation office.

Author contributions

DS analysed the data and wrote the manuscript. HE, RD, GL, EE, BH, FL, DOK, MC, LS, KP, CJ, FNA, JC provided patient information. JOD, KR, ML and NOC provided critical appraisal of the manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] https://covid19.who.int./WHO, 2021.
[2] J. Lopez Bernal, N. Andrews, C. Gower, C. Robertson, J. Stowe, E. Tessier, et al., Outcome after Ad26.COV2.S vaccination, N. Engl. J. Med. 384 (20) (2021) 1964–1966.
[3] X. Gao, P. Koulikis, N. Xu, R.D. Minshall, R. Sandoval, S.M. Vogel, et al., Reversibility of increased microvesicle permeability in response to VE-cadherin disassembly, Am. J. Physiol. Lung Cell. Mol. Physiol. 279 (6) (2000) L1218–L1225.
[4] A.A. Stepanenko, V.V. Dmitrenko, HER2/3 in cell biology and cancer research: phenotype, karyotype, tumorigenesis, and stress-induced genome-phenotype evolution, Gene 569 (2015) 182–190.
[5] G. Lippi, Favaloro E.J. Venous, Arterial Thromboses, Two sides of the same coin? Semin. Thromb. Hemost. 34 (3) (2018) 239–248.
[6] https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-a-guide-on-vaccine-related-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting#a_3125908.
[7] J.O. Dines, J.B. Bussel, SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia, N. Engl. J. Med. 384 (23) (2021) 2254–2266.
[8] J. Thromb. Haemostasis 19 (7) (2021) 1819. Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VITT) – a novel clinicopathologic entity with heterogeneous clinical presentations, Br. J. Haematol. (2021) n/a(n/a).
[9] U.J. Sachs, N. Cooper, A. Cavallina, J. Müller, B. Potzsch, A. Tiede, et al., PF4-Dependent immunooassays in patients with vaccine-induced thrombotic thrombocytopenia: results of an interlaboratory comparison, Thromb. Haemostasis 2015 (5) (2021), e12529.
[10] J. Oldenburg, R. Klammoth, F. Manger, L. Alibetti, C. von Auer, C. Ay, et al., Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GHT, Hämatoästologie 41 (3) (2021) 184–189.
[11] Panel) EHH, Guidance from the expert Haematoology Panel (EHP) on covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). https://bsh-society.org/media/19718/guidance-v20-20210528-002pdf, 2021 version 2.0.
[12] Haematoology AsO, Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombocytopenia and thrombosis). https://www.hematology.org/covid-19/vaccine-induced-immune-thromboembolism-thrombosis, (Accessed 28 August 2021).
[13] I. Nary, U.J. Sachs, D.M. Arnold, S.E. McKenzie, P. Choi, K. Althaus, et al., Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC subcommittee on platelet immunology, J. Thromb. Haemostasis 19 (6) (2021) 1585–1588.
[14] (NICE) NICEi, COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). www.nice.org.uk/guidance/ng200, published 29 july 2021.
[15] S. Handtke, M. Wolff, C. Zaninetti, J. Wesche, L. Schönborn, K. Aubich, et al., A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCoV-19 vaccination, Blood 137 (2021) 3565–3569.
[16] K. Althaus, P. Möller, G. Uzun, A. Singh, A. Beck, M. Bettag, et al., Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia, Haematologica 106 (8) (2021) 2170–2179.
[17] A. Bourguignon, D.M. Arnold, T.E. Warkentin, J.W. Smith, T. Pannu, J.M. Shrum, et al., Adjunct immune globulin for vaccine-induced immune thrombocytopenia, N. Engl. J. Med. 385 (8) (2021) 720–728.
[18] R.J. Perry, A. Tamborska, B. Singh, B. Craven, R. Margolid, P. Farraj, et al., Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021.
[19] T.E. Warkentin, M. Pai, I.A. Linkins, Direct oral anticoagulants for treatment of thrombosis and in-hospital mortality, Blood 125 (9) (2015) 1476–1483.
[20] M. Napolitano, G. Saccullo, M. Marietta, M. Carpenedo, G. Castaman, E. Cerchiara, et al., A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCoV-19 vaccination, Blood 137 (2021) 3565–3569.
[21] A.M. Pishko, D.S. Lefler, P. Gimotty, K. Paydary, S. Fardin, G.M. Arepally, et al., Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with vaccine-related thrombosis, J. Thromb. Haemostasis 15 (11) (2017) 2099–2114.
[22] M. Hogan, J.S. Berger, Heparin-induced thrombocytopenia (HIT): review of Hamilton experience and literature review, Blood 130 (9) (2017) 1845–1860.
[23] M. Sanguineti, W. van der Giessen, R. van Setten, H. Sauer, et al., AAT-Dependent immunoassays in patients with vaccine-induced thrombotic thrombocytopenia: results of an interlaboratory comparison, Thromb. Haemostasis 1 (1) (2017) 134–140.
[24] K. Doucette, C.B. DeStefano, N.A. Jain, A.L. Cruz, V. Malkovska, K. Fitzpatrick, Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG), Res. Pract. Thrombosis Haemostasis 1 (1) (2017) 134–137.
[25] K. Doucette, C.B. DeStefano, N.A. Jain, A.L. Cruz, V. Malkovska, K. Fitzpatrick, Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG), Res. Pract. Thrombosis Haemostasis 1 (1) (2017) 134–137.
[44] M. Gonzales, A. Pipalia, A. Weil, Refractory heparin-induced thrombocytopenia with cerebral venous sinus thrombosis treated with IVIG, steroids, and a combination of anticoagulants: a case report, J Investig Med High Impact Case Rep 7 (2019), 232470961832324.

[45] M. Carcao, M. Silva, M. David, R.J. Klaassen, M. Steele, V. Price, et al., IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP, Blood Adv 4 (7) (2020) 1492–1500.

[46] C.J. Patriquin, V. Laroche, R. Selby, J. Pendergrast, D. Cotton, et al., Therapeutic plasma exchange in vaccine-induced immune thrombocytopenia, N. Engl. J. Med. 385 (9) (2021) 857–859.

[47] A.M. Schell, M. Petras, Z.M. Szczepiorkowski, D.L. Ornstein, Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy, Transfus. Apher. Sci. 49 (2) (2013) 185–188.

[48] I.J. Welsby, E.F. Krakow, J.A. Heit, E.C. Williams, G.M. Arepally, S. Bar-Yosef, et al., The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. Journal of thrombosis and haemostasis : JTH 15 (1) (2017) 57–65.

[49] C.W. Smith, C. Kardey, Y. Di, G.C. Lowe, W.A. Lester, S.P. Watson, et al., Platelet activation by vaccine-induced immune thrombotic thrombocytopenia (VITT) patient serum is blocked by COX, P2Y12 and kinase inhibitors, medRxiv 2021 (2021), 04.24.21255655.

[50] B.H. Chong, P.A. Castaldi, Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets, Br. J. Haematol. 64 (2) (1986) 347–354.

[51] T.J. Stalker, E.A. Traxler, J. Wu, K.M. Wannemacher, S.L. Cermignano, R. Voronov, et al., Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network, Blood 121 (10) (2013) 1875–1885.

[52] J. Thachil, COVID-19 vaccine-induced immune thrombosis with thrombocytopenia (VITT) and the shades of grey in thrombus formation, Semin. Thromb. Hemost. (2021), https://doi.org/10.1055/s-0041-1735453.

[53] A. Cuker, G.M. Arepally, B.H. Chong, D.B. Cines, A. Greinacher, Y. Gruel, et al., American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia, Blood Adv 2 (22) (2018) 3360–3392.

[54] L. Schonborn, T. Thiele, L. Kaderali, A. Greinacher, Decline in pathogenic antibodies over time in VITT, N. Engl. J. Med. (2021).

D. Swan et al. Thrombosis Update 5 (2021) 100086